Monitor the pace of ATM draws and subsequent filings for actual share sales. The company's cash runway into Q3 2027 suggests near-term dilution is likely to fund ongoing clinical trials. Watch for Phase 2b topline results for GX-03 in Q1 2027 as a potential catalyst.
Drug in focus
TTRX drug pipeline →GX-03
▲ Bullish Named in this S-3- Impact
- Phase
- Phase 2
- Time to market
- ~3-4 years if Phase 2 succeeds; GX-03 needs Phase 3 trials (estimated $55-60M R&D spend per company guidance) and FDA approval. Cash runway only through Q1-Q3 2027, so additional financing likely needed.
- Next catalyst
- None dated
What to watchGX-03 Phase 2 topline data in Q4 2026 is the next binary inflection point. Interim data (June 2026) showed strong efficacy signals (92.6% EASI-50, 70.4% EASI-75, 44.4% EASI-90 at week 4) with zero serious adverse events. The expanded Stage 2 (~120-135 patients) and planned FDA Type-B meeting make Q4 the key catalyst window. Monitor enrollment updates and any competitive landscape shifts from approved topicals (ruxolitinib, roflumilast).
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $9.79entry
- T+1 · 7d ago +1.33%α +1.70% · $9.92
- T+5 · 18h ago −12.67%α −10.97% · $8.55
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Turn Therapeutics filed a universal shelf registration statement on Form S-3 to offer up to $150M in securities, including a $50M at-the-market (ATM) equity program with TD Cowen. The company is a pre-revenue clinical-stage biotech with a net loss of $6.2M in Q3 2026 and only $10.4M in cash, making this a capital raise to fund operations and clinical trials into Q3 2027. The filing signals significant potential dilution for existing shareholders.
Key Financial Metrics
Key Facts
- Shelf registration for up to $150M in securities, including a $50M ATM with TD Cowen.
- Company reported a net loss of $6.2M in Q3 2026, wider than $1.9M loss in Q3 2025.
- Cash and cash equivalents of $10.4M as of September 30, 2026, funding operations into Q3 2027.
- Pre-revenue clinical-stage biotech with no approved products.
- 10 offering/registration filings in the last 24 months, indicating frequent capital needs.
- Market cap of $273M; $50M ATM represents ~18% of market cap in potential dilution.
- Proceeds used for general corporate purposes including R&D, clinical development, and working capital.
Financial Impact
Up to $150M in potential securities issuance, with $50M ATM representing ~18% of current market cap; net loss of $6.2M in Q3 2026 vs $1.9M in Q3 2025.
Risk Factors
- Significant dilution from potential $50M ATM issuance (up to ~5.3M shares at $9.48).
- Pre-revenue status with widening losses and reliance on capital markets for funding.
- Frequent past offerings suggest ongoing capital needs; 10 filings in 24 months.
- Clinical-stage risk: GX-03 Phase 2b results not expected until Q1 2027.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001213900-26-117232 |
| Document: ea030998001ex4-5.htm | 0001213900-26-117232 |
| Document: ea030998001ex1-2.htm | 0001213900-26-117232 |
Track record
19 reports on TTRX
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +115.10% at T+60 after the May 18, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry $8.55 Now $8.55 −0.00% settles Feb 16
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $9.92 Now $8.55 −13.81% settles Feb 8
- Nov 9, 20267d ago S-3 Bearish 6/10 Viewing Entry $9.79 Now $8.55 +12.67% settles Feb 5
- Nov 9, 20267d ago S-3 Bearish 6/10 Entry $9.79 Now $8.55 +12.67% settles Feb 5
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $9.79 Now $8.55 −12.67% settles Feb 5
- Oct 19, 202628d ago DEF 14A Neutral 3/10 Entry $10.47 Now $8.55 −18.34% settles Jan 15
- Oct 6, 20265w ago 8-K Neutral 5/10 Entry $12.10 Now $8.55 −29.34% settles Jan 4
- Sep 10, 20269w ago 8-K Neutral 3/10 Entry $13.38 Now $8.55 −36.10% settles Dec 4
- Sep 9, 20269w ago 8-K Bullish 5/10 Entry $13.75 Now $8.55 −37.82% settles Dec 3
- Aug 18, 202612w ago 8-K Neutral 4/10 Entry $9.99 to $9.92 Now $8.55 −14.41% ▼ −0.70% +1.34% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers